{"slideshow_credits": null, "snippet": "The Irish drug company Elan, which wants to remake itself, is selling its interest in its highly successful multiple sclerosis drug Tysabri to its American partner, Biogen Idec.", "abstract": "Irish drug company Elan, which wants to remake itself, is selling its interest in its highly successful multiple sclerosis drug Tysabri for more than $3.25 billion to its American partner, Biogen Idec.", "section_name": "Business Day", "print_page": "6", "document_type": "article", "byline": {"person": [], "organization": "REUTERS", "original": "By REUTERS", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/02/07/business/tysabri-drug-sold-by-irish-maker-to-biogen-idec.html", "lead_paragraph": "The Irish drug company Elan, which wants to remake itself, is selling its interest in its highly successful multiple sclerosis drug Tysabri to its American partner, Biogen Idec.", "headline": {"seo": "Tysabri Drug Sold by Irish Maker to Biogen Idec", "main": "Irish Maker Sells Its Big MS Drug to Biogen", "print_headline": "Irish Maker Sells Its Big MS Drug to Biogen"}, "_id": "5118a03c00315214fbb8a56b", "word_count": "372", "multimedia": [], "pub_date": "2013-02-07T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Biogen Idec Inc", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Elan Corporation PLC", "name": "organizations", "is_major": "Y", "rank": "2"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Tysabri (Drug)", "name": "subject", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}